Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new safety profiles observed. According to research presented at the European ...

reinforce earlier findings of the benefits of the drug – trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate – in these patients, trial leaders say. The results of the trial, dubbed the DESTINY ...

Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non ... Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Six late-breaking presentations across lung and breast cancer trials of DXd ADCs, including two Presidential Symposia at WCLC featuring datopotamab deruxtecan data First ever clinical data from ...

Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...

Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...

In fact, if anything at all, being able to manage the demands of study while balancing full-time work and personal/family demands only serves to showcase your strong commitment to professional ...

design thinking, history and research. Graphic design is used in everything from branding and identity, books and magazines, advertising, packaging, web and interface design, motion graphics, and just ...